Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dexpanthenol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Arm 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Dexpanthenol (Sinecort, BAY81-2996) | DRUG | 1 squeeze of Sinecort cream sufficient to cover the area of the application chamber, (=50 mikro liter) |
| Positive control, Na-laurylsulfat-solution | DRUG | 50 mikro liter of 0.5 % Sodium-laurylsulfate-solution |
| Untreated skin under application chamber | DEVICE | Application of treatment chamber as in arm 1 and arm 2 on untreated skin |
Inclusion Criteria: * Age of at least 18 years * Skin type I, II, or III according to Fitzpatrick * Subjects of childbearing potential must use an acceptable method of contraception. Hormonal or oral contraceptive drugs, intra-uterine devices (IUD) and abstinence are considered acceptable methods o...
Dexpanthenol is a small molecule being developed by Bayer AG for use in healthy volunteers. It is currently in Phase 1 clinical development as an investigational drug. The compound is being studied for its safety profile in a clinical trial setting, though no specific therapeutic indication has been established in the available data.
Dexpanthenol is being developed by Bayer AG, a multinational pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY. The company is conducting clinical research on this small molecule compound as part of its early-stage development pipeline.
Dexpanthenol is currently in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The compound is in early-stage testing to evaluate its safety and tolerability in human subjects, which is the primary objective of Phase 1 trials.
Dexpanthenol has one completed Phase 1 clinical trial registered under NCT00885937. This trial, titled "Comparative Safety Study of New Sinecort Formulation Versus Positive Control," enrolled 33 healthy volunteers in Germany. The study was placebo-controlled and randomized, though it was not double-blinded. The trial has been completed.
Dexpanthenol is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The compound has completed one early-stage clinical trial, but it has not yet demonstrated sufficient safety and efficacy data to support regulatory approval. Further clinical studies would be required before any approval could be considered.